<DOC>
	<DOC>NCT00832221</DOC>
	<brief_summary>The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.</brief_summary>
	<brief_title>Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Raclopride</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>Normal MRI scan Body mass index 1930 kg/m2 and weight of 50100 kg Clinically normal physical findings, medical history and laboratory values Trauma or sickness last 2 weeks before the first PET examination. A history or presence of neurological, haematological, psychiatric, gastrointestinal, hepatic, pulmonary, renal disease or other condition as judged by the Investigator Any previous participation in a PET study Subjects suffer from claustrophobia</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>PET</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Depression</keyword>
	<keyword>SEROQUEL</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Drug profile comparison</keyword>
</DOC>